A platform led by Professor Jörg Fritz of McGill University to stimulate the discovery and development of new RNA vaccines. 

26 June 2025

Vaccines are essential for preventing infections and represent a cornerstone of strategies aimed at preparing for future epidemics and pandemics. The development of new RNA vaccines against emerging pathogens relies on the rapid identification of antigenic targets capable of eliciting effective protection against infection. However, this crucial step is often limited by the lack of efficient screening tools. Moreover, there is a need for a preclinical platform to evaluate new formulations and the effectiveness of RNA vaccines. 

Optimization and Scale-Up of RNA Therapeutics Through Next-Generation Manufacturing

23 June 2025

RNA-based therapies and vaccines represent a versatile and preferred approach to addressing several major public health challenges. However, their production requires RNA to be encapsulated, stabilized, and delivered to the body using nanosuspensions complex structures that must be custom-formulated depending on the targeted organ or cells. This level of customization presents a significant challenge for large-scale production.

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

18 June 2025

Montréal, June 18, 2025, Médicament Québec is proud to announce the awarding of two significant grants, supported by the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE), for collaborative and structuring activities as part of its participation in La CELLULE, an initiative of the AReNA hub.